0.772
0.18%
-0.0002
전일 마감가:
$0.7722
열려 있는:
$0.8
하루 거래량:
22,074
Relative Volume:
0.67
시가총액:
$147.34M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+47.92%
1개월 성능:
+65.76%
6개월 성능:
+0.00%
1년 성능:
+0.00%
Lakeshore Biopharma Co Ltd Stock (LSB) Company Profile
Lakeshore Biopharma Co Ltd 주식(LSB)의 최신 뉴스
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 - The Manila Times
Lakeshore Biopharma to Hold an Extraordinary General Meeting of Shareholders on September 27, 2024 - StockTitan
LakeShore Biopharma names Xu Wang as new CEO - Investing.com India
LakeShore Biopharma names Xu Wang as new CEO By Investing.com - Investing.com Canada
LakeShore Biopharma Announces Leadership Transitions - Kilgore News Herald
LakeShore Biopharma Announces Leadership Transitions - StockTitan
Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Short Interest Update - Defense World
Short Interest in Lakeshore Biopharma Co., Ltd. (NASDAQ:LSB) Rises By 20.1% - Defense World
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - Longview News-Journal
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - PR Newswire
LakeShore Biopharma Announces Financial Results for Fiscal Year 2024 - Morningstar
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - Simply Wall St
ROSEN, LEADING INVESTOR COUNSEL, Encourages YS Biopharma Co., Ltd. f/k/a Summit Healthcare Acquisition Corp. Investors to Inquire About Securities Class Action InvestigationYS, SMIH - Marketscreener.com
LakeShore Biopharma (NASDAQ:LSB) Stock Quotes, Forecast and News Summary - Benzinga
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - Macau Business
LakeShore Biopharma to Hold an Extraordinary General Meeting on July 25, 2024, Pursuant to Shareholders' Requisition - PR Newswire
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - Yahoo Finance UK
LakeShore Biopharma Insider Ups Holding By 3,083% During Year - Yahoo Finance
LakeShore Biopharma Co., Ltd (NASDAQ:LSB) Looks Inexpensive After Falling 36% But Perhaps Not Attractive Enough - Simply Wall St
LakeShore Biopharma Announces Executive ReshuffleTipRanks.com - TipRanks
The Hunt for Virus Treatments Continues Post Covid-19 - Exeter Lakeshore Times-Advance
Exploring High Insider Ownership In US Growth Companies - Simply Wall St
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): Are Analysts Optimistic? - Simply Wall St
LakeShore Biopharma Co., Ltd (NASDAQ:LSB): When Will It Breakeven? - Yahoo Finance
Does Dun & Bradstreet Holdings (NYSE:DNB) Have A Healthy Balance Sheet? - Simply Wall St
YS, SMIH INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages YS Biopharma Co., Ltd. f/k/a ... - Marketscreener.com
YS Biopharma announces name change to 'LakeShore Biopharma'TipRanks.com - TipRanks
YS Biopharma to change legal name to LakeShore Biopharma (NASDAQ:YS) - Seeking Alpha
YS Biopharma Announces Name Change to LakeShore Biopharma USAEnglish - PR Newswire
YS Biopharma Announces Name Change to LakeShore Biopharma - PR Newswire
YS Biopharma Announces Results of Extraordinary General Meeting - Thailand Business News
YS Biopharma Approves Major Corporate ChangesTipRanks.com - TipRanks
YS Biopharma Announces Results of Extraordinary General Meeting APACEnglish - PR Newswire
YS Biopharma Announces Results of Extraordinary General Meeting - PR Newswire
YS Biopharma to Hold Extraordinary General Meeting on May 21, 2024 and Announces the Appointment of Interim Chief Executive Officer - PR Newswire
Arrow Electronics First Quarter 2024 Earnings: Misses Expectations - Simply Wall St
YS Biopharma Receives Additional 180 Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule - PR Newswire
YS Biopharma Announces Unaudited Financial Results for the First Nine Months of Fiscal Year 2024 - PR Newswire
YS Biopharma Granted Phase I Clinical Trial License of Therapeutic Chronic Hepatitis B Virus Vaccine - PR Newswire
YS Biopharma Announces Positive Interim Results of Pivotal Phase 3 Clinical Study of PIKA Rabies Vaccine - PR Newswire
YS Biopharma Announces Full Repayment of US$40,000,000 Loan Facility - PR Newswire
Sprinklr Full Year 2024 Earnings: EPS Beats Expectations - Simply Wall St
YS Biopharma Announces Board Changes and Strategic Leadership Appointments in Chinese Subsidiaries - PR Newswire
YS Biopharma Announces Results of Extraordinary General Meeting held on February 22, 2024 - PR Newswire
YS Biopharma Responds to a Notice of Extraordinary General Meeting of Shareholders of YS Biopharma Co., Ltd. - PR Newswire
YS Biopharma Announces US$40 Million Private Placement Financing - PR Newswire
Sagimet Bio stock surges after trial win for NASH drug - Seeking Alpha
YS Biopharma Responds to Unauthorized Press Release Regarding Extraordinary General Meeting - PR Newswire
ADIA-backed Lake Shore confident about turning around Koregaon Park mall - The Financial Express
YS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDA - PR Newswire
Virtuous Retail in talks to sell malls for about $500 million - IndiaTimes
Lakeshore Biopharma Co Ltd (LSB) 재무 분석
Lakeshore Biopharma Co Ltd (LSB)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):